查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403452

到 2030 年結核病診斷市場預測：按產品類型、測試類型、階段、最終用戶和地區進行的全球分析

Tuberculosis Diagnostics Market Forecasts to 2030 - Global Analysis By Product Type, Test Type, Disease Stage, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球結核病診斷市場規模為 20.7 億美元，預計到 2030 年將達到 34.6 億美元，預測期內複合年成長率為 7.6%。

結核病是一種由結核分枝桿菌引起的傳染性疾病，主要攻擊患者的肺部、脊椎和大腦。結核病診斷客觀、準確地辨識結核感染。結核病診斷有助於區分結核病與其他症狀相似的呼吸道疾病，減少誤診和不必要的治療。

根據世界衛生組織《2022年全球結核病報告》，2021年全球約有1,060萬人感染結核病，比2020年報告的1,010萬人增加了4.5%。

抗藥性結核病

多重抗藥性結核病 (MDR-TB) 和廣泛抗藥性結核病 (XDR-TB) 等抗藥性結核菌株的出現，需要準確、快速的診斷檢測。抗藥性結核分枝桿菌對標準第一線抗結核藥物沒有反應，因此檢測和適當的治療至關重要。使用傳統診斷方法難以識別抗藥性結核分枝桿菌，可能會導致治療延遲或無效、感染傳播增加以及患者預後不佳。因此，對能夠準確檢測抗藥性結核病的先進診斷方法的需求不斷成長。

高成本

與痰液塗片顯微鏡等傳統方法相比，分子和基因型測試等先進診斷技術通常價格昂貴。這些測試的成本不僅包括檢測套組，還包括執行這些測試所需的設備、實驗室基礎設施和技術人員。因此，高成本可能會阻礙醫療保健提供者實施更先進、更精確的診斷技術，從而阻礙市場成長。

先進的診斷技術

聚合酶鏈反應（PCR）和核酸增幅檢查（NAAT）等分子技術的使用提高了結核病的檢測靈敏度，甚至可以診斷細菌計數較低的病例。此外，即時檢測的改進使診斷更接近患者。這在資源有限的環境中特別有利，因為它減少了從治療開始到結果的時間。因此，這些先進的診斷技術將加速市場成長。

柱頭

對傳播方式的誤解、對感染的恐懼以及與貧困和邊緣群體的聯繫是導致結核病恥辱的一些因素。然而，這種恥辱可能導致個人不願透露症狀、尋求醫療保健和接受結核病診斷檢測。由於擔心社會排斥、歧視和不利的社會觀念，人們可能無法接受結核病診斷服務。這可能會延誤診斷並導致疾病傳播。這些因素都阻礙了市場需求。

COVID-19 的影響

COVID-19大流行對結核病診斷市場產生了重大影響。雖然它最初擾亂了醫療保健系統並轉移了結核病診斷的資源，但它也凸顯了強大的診斷基礎設施的重要性。隨著大流行的消退，人們將越來越認知到加強醫療保健系統的必要性，這可能對結核病診斷有長期好處。此外，COVID-19 可能加速了遠端醫療和數位醫療的進步，這可能會提高我們診斷結核病的能力。

診斷測試領域預計將在預測期內成為最大的領域

診斷測試方法部分估計佔最大佔有率。世界各地的大多數醫院和診所都進行基於培養的測試以及塗片顯微鏡檢查。這使得它成為無法獲得更先進診斷技術的患者診斷結核病的可行選擇。此外，塗片顯微鏡檢查和基於培養的測試仍然是診斷結核病最準確的測試，儘管核酸增幅檢查(NAAT) 等更新的測試正變得越來越廣泛。

痰液塗片顯微鏡檢查領域預計在預測期內複合年成長率最高。

痰液塗片顯微鏡領域預計在預測期內將出現良好的成長。痰液塗片鏡是一種簡單且經濟有效的技術，用於檢測痰液樣本中的抗酸桿菌（AFB），有助於診斷肺結核。痰液塗片顯微鏡檢查不需要複雜的測試基礎設施或昂貴的設備，因此可以在資源有限的環境中廣泛使用。此外，快速的結果使醫護人員能夠快速開始結核病治療，減少感染並改善患者的治療結果。

比最大的地區

亞太地區由於疾病的負擔高且擴散迅速，在市場上佔據主導地位並佔據最大的市場佔有率佔有率。該地區多個國家結核病發病率上升是推動市場收益增加的主要因素之一。此外，該地區的高死亡率和低人類發展指數是支撐市場收益成長的關鍵因素。該地區受影響的國家包括孟加拉、中國、印度、印尼、巴基斯坦和菲律賓。

複合年成長率最高的地區：

由於成人和兒童結核病患者病率上升，預計北美在預測期內將出現有益的成長。該地區的醫學研究機構正在擴大取得與病原體特異性代謝途徑相關的有價值的發現。這可能是專注於檢測病原體免疫反應、細菌生長或細菌核酸擴增的現有技術的替代方案。此外，人工智慧與奈米技術的結合可以大大幫助改善北美患者的結核病診斷流程。

提供免費客製化：

訂閱此報告的客戶將收到以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球結核病診斷市場：依產品類型

  • 痰液塗片鏡檢
  • 培養診斷
  • 快速分子診斷
  • 其他產品類型

第6章全球結核病診斷市場：依測試類型

  • 檢測潛伏感染
  • 射線照相
  • 核酸檢測
  • 噬菌體測定
  • 診斷測試方法
  • 抗藥性檢測
  • 細胞激素檢測分析
  • 其他測試類型

第7章全球結核病診斷市場：依階段

  • 活動性結核病
  • 潛伏性結核病

第8章全球結核病診斷市場：依最終用戶分類

  • 醫生辦公室
  • 醫院和診斷實驗室
  • 參考實驗室
  • 學術研究設施
  • 其他最終用戶

第9章全球結核病診斷市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Becton Dickinson and Company
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Oxford Immunotec Ltd.
  • Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • BioMerieux SA
  • Akonni Biosystems Inc.
  • Cepheid Inc.
  • Alere Inc.
  • PAR Pharmaceuticals
  • Hain Life Science.
  • Lionex GmbH
Product Code: SMRC24677

According to Stratistics MRC, the Global Tuberculosis Diagnostics Market is accounted for $2.07 billion in 2023 and is expected to reach $3.46 billion by 2030 growing at a CAGR of 7.6% during the forecast period. Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis and it mainly attacks the lungs, spine, and brain of the patients. Tuberculosis diagnostics provide objective and precise identification of TB infection. They help differentiate TB from other respiratory diseases with similar symptoms, reducing misdiagnosis and unnecessary treatments.

According to the WHO Global Tuberculosis report 2022, in 2021, approximately 10.6 million individuals fell ill with tuberculosis globally, representing 4.5% rise from 10.1 million cases reported in 2020.

Market Dynamics:

Driver:

Drug-resistant TB

The emergence of drug-resistant strains, such as multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), has created a need for accurate and rapid diagnostic tests. Drug-resistant TB strains do not respond to the standard first-line anti TB medications, making their detection and appropriate treatment critical. Traditional diagnostic methods may not be effective in identifying drug-resistant strains, leading to delayed or ineffective treatment, increased transmission, and poor patient outcomes. As a result, there is a growing demand for advanced diagnostics that can accurately detect drug-resistant TB.

Restraint:

High cost

Advanced diagnostic technologies, such as molecular tests and genotypic assays, often come with a higher price tag compared to traditional methods like sputum smear microscopy. The cost of these tests includes not only the test kits but also the equipment, laboratory infrastructure, and skilled personnel required for their implementation. Therefore, high costs may deter healthcare providers from implementing more advanced and precise diagnostic techniques, impeding the growth of the market.

Opportunity:

Advanced diagnostic technologies

The utilization of molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), allows for the detection of TB with enhanced sensitivity, enabling diagnosis even in cases with low bacterial loads. Additionally, improvements in point-of-care testing bring diagnostics closer to the patient. This is especially advantageous in settings with limited resources because it shortens the time between starting treatment and receiving results. Therefore, these advanced diagnostic technologies accelerate market growth.

Threat:

Stigma

Misconceptions regarding the mode of transmission, fear of infection, and associations with poverty or marginalized groups are some of the factors that contribute to the stigma surrounding tuberculosis. However, this stigma can lead to reluctance among individuals to disclose their symptoms, seek healthcare, or undergo TB diagnostic testing. People may be unable to receive TB diagnostic services because of fear of social exclusion, discrimination, or unfavourable societal perceptions. This can postpone diagnosis and contribute to the disease's spread. These factors hamper market demand.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the tuberculosis diagnostics market. While it initially disrupted healthcare systems, diverting resources away from TB diagnostics, it also highlighted the importance of robust diagnostic infrastructure. Long-term benefits for TB diagnostics could result from increased awareness of the need for strengthening healthcare systems as the pandemic fades. Furthermore, COVID-19 may have accelerated advancements in telemedicine and digital health, which could improve the capacity for tuberculosis diagnosis.

The diagnostic laboratory methods segment is expected to be the largest during the forecast period

The diagnostic laboratory methods segment is estimated to hold the largest share. Most hospitals and clinics globally provide culture-based tests as well as smear microscopy. Due to this, they are a viable choice for tuberculosis diagnosis for patients who might not have access to more sophisticated diagnostic procedures. Moreover, while newer tests, such as nucleic acid amplification tests (NAATs), are becoming more widely available, smear microscopy and culture-based tests are still considered to be the most accurate tests for diagnosing tuberculosis.

The sputum smear microscopy segment is expected to have the highest CAGR during the forecast period

The sputum smear microscopy segment is anticipated to have lucrative growth during the forecast period. It is a simple and cost-effective technique used to detect acid-fast bacilli (AFB) in sputum samples, aiding in the diagnosis of pulmonary TB. Sputum smear microscopy is widely available, even in resource-limited settings, as it does not require sophisticated laboratory infrastructure or expensive equipment. Moreover, it provides rapid results, enabling healthcare providers to initiate TB treatment promptly, reducing transmission, and improving patient outcomes.

Region with largest share:

Asia Pacific dominated the market and accounted for the largest market share due to its high burden as well as the rapid proliferation of this disease. The rising rates of tuberculosis in several of the countries in this region are one of the primary drivers of the increase in market revenue. Furthermore, the high mortality rate and low human development index in this region are important factors that support the growth in market revenue. Bangladesh, China, India, Indonesia, Pakistan, and the Philippines are among the affected nations in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to the rising prevalence of tuberculosis among adults and children. Medical research institutes in this region are discovering an increasing number of benefits associated with pathogen-specific metabolic pathways. This could serve as a substitute for the existing techniques that focus on the detection of pathogen immune responses, bacterial growth, or bacterial nucleic acid amplification. Additionally, AI and nanotechnology combined significantly aid in improving the tuberculosis diagnosis process among patients in North America.

Key players in the market:

Some of the key players in the Tuberculosis Diagnostics Market include Becton Dickinson and Company, Qiagen NV, Thermo Fisher Scientific Inc., Oxford Immunotec Ltd., Hoffmann-La Roche Ltd., Hologic Inc., BioMerieux SA, Akonni Biosystems Inc., Cepheid Inc., Alere Inc., PAR Pharmaceuticals, Hain Life Science and Lionex GmbH.

Key Developments:

In February 2022 - QIAGEN announced that its QuantiFERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.

In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research & development of infectious disease detection, which is expected to expand the company's product portfolio in the market.

Product Types Covered:

  • Sputum Smear Microscopy
  • Culture-Based Diagnostics
  • Rapid Molecular Diagnostics
  • Other Product Types

Test Types Covered:

  • Detection of Latent Infection
  • Radiographic Method
  • Nucleic Acid Testing
  • Phage Assay
  • Diagnostic Laboratory Methods
  • Detection of Drug Resistance
  • Cytokine Detection Assay
  • Other Test Types

Disease Stages Covered:

  • Active Tuberculosis
  • Latent Tuberculosis

End Users Covered:

  • Physician's Office Laboratories
  • Hospitals and Diagnostic Laboratories
  • Reference Laboratories
  • Academics and Research Facilities
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Tuberculosis Diagnostics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Sputum Smear Microscopy
  • 5.3 Culture-Based Diagnostics
  • 5.4 Rapid Molecular Diagnostics
  • 5.5 Other Product Types

6 Global Tuberculosis Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Detection of Latent Infection
  • 6.3 Radiographic Method
  • 6.4 Nucleic Acid Testing
  • 6.5 Phage Assay
  • 6.6 Diagnostic Laboratory Methods
  • 6.7 Detection of Drug Resistance
  • 6.8 Cytokine Detection Assay
  • 6.9 Other Test Types

7 Global Tuberculosis Diagnostics Market, By Disease Stage

  • 7.1 Introduction
  • 7.2 Active Tuberculosis
  • 7.3 Latent Tuberculosis

8 Global Tuberculosis Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Physician's Office Laboratories
  • 8.3 Hospitals and Diagnostic Laboratories
  • 8.4 Reference Laboratories
  • 8.5 Academics and Research Facilities
  • 8.6 Other End Users

9 Global Tuberculosis Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Becton Dickinson and Company
  • 11.2 Qiagen NV
  • 11.3 Thermo Fisher Scientific Inc.
  • 11.4 Oxford Immunotec Ltd.
  • 11.5 Hoffmann-La Roche Ltd.
  • 11.6 Hologic Inc.
  • 11.7 BioMerieux SA
  • 11.8 Akonni Biosystems Inc.
  • 11.9 Cepheid Inc.
  • 11.10 Alere Inc.
  • 11.11 PAR Pharmaceuticals
  • 11.12 Hain Life Science.
  • 11.13 Lionex GmbH

List of Tables

  • Table 1 Global Tuberculosis Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 4 Global Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 5 Global Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 6 Global Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 7 Global Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 8 Global Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 9 Global Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 10 Global Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 11 Global Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 12 Global Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 13 Global Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 14 Global Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 15 Global Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 16 Global Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 17 Global Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 18 Global Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 19 Global Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 21 Global Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 22 Global Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 23 Global Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 24 Global Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 25 North America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 North America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 27 North America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 28 North America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 29 North America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 30 North America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 31 North America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 32 North America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 33 North America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 34 North America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 35 North America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 36 North America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 37 North America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 38 North America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 39 North America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 40 North America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 41 North America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 42 North America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 43 North America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 North America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 45 North America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 46 North America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 47 North America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 48 North America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Europe Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Europe Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 51 Europe Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 52 Europe Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 53 Europe Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 54 Europe Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 55 Europe Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 56 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 57 Europe Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 58 Europe Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 59 Europe Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 60 Europe Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 61 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 62 Europe Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 63 Europe Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 64 Europe Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 65 Europe Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 66 Europe Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 67 Europe Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 68 Europe Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 69 Europe Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 70 Europe Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 71 Europe Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 72 Europe Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 73 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 75 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 76 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 77 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 78 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 79 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 80 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 81 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 82 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 83 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 84 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 85 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 86 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 87 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 88 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 89 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 90 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 91 Asia Pacific Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 93 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 94 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 95 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 96 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 97 South America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 98 South America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 99 South America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 100 South America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 101 South America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 102 South America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 103 South America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 104 South America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 105 South America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 106 South America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 107 South America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 108 South America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 109 South America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 110 South America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 111 South America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 112 South America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 113 South America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 114 South America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 115 South America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 116 South America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 117 South America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 118 South America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 119 South America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 120 South America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 121 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 122 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 123 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 124 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 125 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 126 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 127 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 128 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 129 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 130 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 131 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 132 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 133 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 134 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 135 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 136 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 137 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 138 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 139 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 140 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 141 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 142 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 143 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 144 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)